Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. reports developments in women's health diagnostics, with news centered on its PreTRM® Test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies. The company uses proteomics, bioinformatics and pregnancy biomarker information to support maternal and neonatal health.
Recurring updates include financial results, commercial adoption and payer engagement for PreTRM, clinical evidence from the PRIME study and related publications, investor presentations, healthcare conference activity, capital allocation and financing actions supporting commercialization.
Sera Prognostics Inc., a company focused on improving maternal and neonatal health, will report first quarter fiscal year 2024 financial results on May 8, 2024. The conference call and webcast will discuss operational highlights, financial results, and key topics at 5:00 p.m. Eastern Time. Details for the call are provided for both US domestic and international callers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.